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Abstract
Local anesthetic systemic toxicity, due to misapplication of local anesthetic in an otherwise
routine procedure, can result in deleterious effects. Although improved regional anesthesia
techniques, effective test-dosing, and availability of less toxic local anesthetics have resulted in a
decline in local anesthetic toxicity rates, adverse events do occur. A comprehensive review of
literature was conducted and current research findings and documented case studies were
systematically reviewed. The “lipid sink” phenomenon is the most widely accepted theoretical
framework surrounding intravenous lipid emulsion treatment for local anesthetic induced
cardiovascular collapse (Rothschild, Bern, Oswald, & Weinberg, 2010). Current evidence
suggests that immediate infusion of lipid emulsion should be considered when clinical signs of
local anesthetic toxicity manifest. By relaying information surrounding practice guidelines on
local anesthetic systemic toxicity, anesthesia practitioners will have an improved understanding
of local anesthetic systemic toxicity clinical diagnosis and lipid emulsion infusion as a treatment
modality.
Keywords: intravenous lipid emulsion, local anesthetics, local anesthetic systemic
toxicity, local anesthetic toxicity, lipid sink, lipid infusion
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Lipid Emulsion Infusion as Treatment for Local Anesthetic Systemic Toxicity
Emerging technologies in regional anesthesia and the increasing popularity of
perioperative regional anesthesia technique renders importance of anesthesia provider vigilance
in both detection and treatment of potentially catastrophic complications of regional anesthesia.
Although serious side effects associated with local anesthetic administration are rare, it is
prudent that anesthesia providers remain up-to-date with the latest research and guidelines in
resuscitation of local anesthetic systemic toxicity (LAST) with intravenous lipid emulsion.
Purpose
Because local anesthetic toxicity remains a clinical concern when performing regional
anesthesia, it is imperative that Certified Registered Nurse Anesthetists (CRNAs) are vigilant in
recognizing signs and symptoms of LAST and are able to demonstrate both effective and
efficient administration of lipid emulsion therapy in resuscitation of significant local anesthetic
toxicity.
The purpose of this independent project is to improve clinical practice by providing
current and future anesthesia practitioners medical literature involving the seriousness of local
anesthetic toxicity and the institution of intravenous lipid emulsion therapy as a beneficial
treatment modality. The information gathered was presented to clinicians and ancillary operating
room staff at local anesthetic toxicity workshops conducted at Sanford Health, Fargo, North
Dakota, and will be delivered at the North Dakota Association of Nurse Anesthetists bi-annual
meeting in Bismarck, North Dakota.
The ultimate goal for the delivery of current, reputable evidence combined from the
literature is to guide anesthesia professionals in the execution of rapid problem recognition and
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efficiency in the resuscitation process, including guidelines for an appropriate lipid emulsion
therapy regimen.
Significance
Although emerging technologies in regional anesthesia may potentially improve the
efficacy and safety of regional anesthesia, the reduction in the number of clinically important
LAST events have not been correlated. Unfortunately, local anesthetic toxicity continues to be a
major contributing source of morbidity and mortality in regional anesthesia practice. According
to Varela and Burns (2010), the incidence of local anesthetic toxicity ranges from 7.5 to 20 per
10,000 peripheral nerve blocks and about 4 per 10,000 epidural blocks, however, the incidence
may be underreported (Varela & Burns, 2010, p. 361). An American Society of
Anesthesiologists closed claim analysis report recently attributed one-third of claims for death or
brain damage associated with regional anesthesia to local anesthetic systemic toxicity (Lee,
Posner, Chaney, Caplain, & Domino, 2008). As evidenced by the statistics relayed above, LAST
is a rare and potentially fatal complication of regional anesthesia. A recent survey conducted by
Corcoran et al. (2006) concluded “wide variability in preparedness for local anesthetic toxicity
and lack of consensus for treatment” (p. 1326) among anesthesiology departments in the United
States. In order to appropriately manage a local anesthetic induced cardiac toxicity crisis,
clinicians must be relevant in practice in effectively treating one of the most devastating
complications of regional anesthesia.
Theoretical Framework
Initially devised in 1998 by Guy Weinberg, MD, the “lipid sink” phenomenon is the most
widely accepted mechanism of action for lipid infusion as a treatment for local anesthetic
toxicity (Rothschild et al., 2010). Weinberg, VadeBoncouer, Ramaraju, Garcia-Amaro and Cwik
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(1998), provided direct evidence that lipids had the ability to counteract the toxic effects of
bupivacaine in the bloodstream in a rat model (as cited in Manavi, 2010). The observations made
by this group of investigators suggested the potential for treatment of bupivacaine induced
cardiotoxicity (Weinberg et al., 1998).
Infusion of lipid emulsion therapy can be instrumental in the resuscitation of local
anesthetic induced systemic toxicity theoretically by acting as a “lipid sink” that draws down the
content of the lipid-soluble local anesthetics from within the cardiac tissue, ultimately improving
cardiac conduction, contractility, and coronary perfusion (Neal et al., 2010). More simply
described, the “lipid sink” theory postulates that infusion of a lipid emulsion creates a separate
lipid compartment within plasma into which local anesthetics are drawn (Manavi, 2010).
The clinical efficacy of lipid emulsion therapy can be attributed to the binding property of
the emulsion. According to Rothschild et al. (2010), the “lipid sink” theory suggests that a large
serum lipid phase extracts local anesthetics from the plasma. Lipophilic drugs, such as local
anesthetics, are drawn into the “lipid sink” and a concentration gradient develops between tissue
and blood which cause the local anesthetic to move away from the heart or brain to the “lipid
sink” (Rothschild et al., 2010, p. 8).
Undoubtedly, the “lipid sink” theory has taken precedence in providing an explanation
for the mechanism of action of intravenous (IV) lipid emulsion therapy in local anesthetic
toxicity. However, historically another theory is that lipid infusions may have metabolic effects
by inhibiting mitochondrial metabolism of lipids, reducing tissue acidosis, and decreasing carbon
dioxide production during times of myocardial ischemia. It has also been suggested that local
anesthetics impair fatty acid production of mitochondria. Infusion of lipid emulsions may work
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to saturate the impaired delivery of fatty acids to restore further production of energy (Felice &
Schumann, 2008).
Definitions
Concepts surrounding local anesthetic induced cardiac toxicity and lipid infusion therapy
can be difficult to comprehend. Although case reports of LAST depict variability in presentation,
the American Society of Regional Anesthesia (ASRA) and Pain Medicine Practice advisory
states the classic description of the clinical diagnosis of systemic toxicity includes “subjective
symptoms of central nervous system excitement such as auditory changes, circumoral numbness,
metallic taste and agitation that progresses to seizures and/or central nervous system depression”
(Neal et al., 2010, p. 155). It is important to note that in the classic presentation of local
anesthetic systemic toxicity, central nervous system toxicity precedes cardiac toxicity. Patients
presenting with LAST seem to follow a common clinical course of symptoms including
tachycardia, followed by a widening QRS pattern on the electrocardiogram, seizure activity and
ultimately asystole (Manavi, 2010). If clinicians familiarize themselves with this consistent
pattern, local anesthetic toxicity may be recognized and intervened in a stage before it becomes
disastrous.
Because the commercial intravenous lipid emulsion products are available in various
concentrations, it is important to define the specifications for lipid emulsions suitable in the
treatment of local anesthetic toxicity. Human case reports predominantly documented
commercial preparation of a 20% lipid emulsion formulation. The 20% formulation of lipid
emulsion contains 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and the
remainder is water (Felice & Schumann, 2008, p. 186). According to the ASRA guidelines
published in 2010, there is no evidence that one trade name formulation of lipid emulsion is
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superior to another (Neal et al., 2010). The recommendations importantly state propofol is not to
be considered as a substitute for lipid emulsion therapy because of its low lipid content, the large
volumes required for resuscitation, and the direct cardiac depressant effects associated with
administration (Neal et al., 2010, p. 158).
Process
A comprehensive review of literature was conducted using major literature search
engines such as Cumulative Index to Nursing and Allied Health Literature (CINAHL) and
National Library of Medicine’s PubMed, Ovid, and Google Scholar databases. American
Association of Nurse Anesthetists journal publications and relevant citations from retrieved
articles were studied to provide supplemental documentation. In addition to peer reviewed
journal articles and a systematic literature review, an online lipid rescue organization was
utilized to investigate and convey clinically relevant data. After the first case of successful
resuscitation using lipid emulsion infusion was published in 2006, Dr. Guy Weinberg created a
website, www.lipidrescue.org, dedicated to informing healthcare providers on the methodology
surrounding lipid emulsion infusion. This online forum provides a means for the anesthesia
community to review and post case reports, medical literature, research data, and guidelines all
aimed toward the prevention, recognition, and treatment of local anesthetic systemic toxicity.
Key search words and phrases included: intravenous lipid emulsion, local anesthetics,
local anesthetic systemic toxicity, local anesthetic toxicity, lipid sink, lipid infusion. The
systematic literature review was geared toward gaining relevant medical literature and case
reports surrounding the mechanisms, diagnosis, and treatment of life-threatening local anesthetic
overdose.
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The information gathered was presented to clinicians and ancillary operating room staff
at three local anesthetic toxicity workshop sessions at Sanford Health, Fargo, North Dakota, and
will be delivered to attendees of the North Dakota Association of Nurse Anesthetists bi-annual
meeting in Bismarck, North Dakota.
Review of Literature
With data from various animal studies and several case reports to testify the effectiveness
of lipids, lipid emulsion therapy is gaining international clinical acceptance as a treatment for
LAST. However, an inconsistency among practices in the management of catastrophic local
anesthetic toxicity remains. Numerous documented animal studies have been conducted to aid in
the formulation of lipid emulsion therapy guidelines as an appropriate intervention for treatment
in the clinical realm. Published case reports, editorials, research, and reviews of lipid emulsion
therapy in the medical literature further aid in both recognizing and treating life threatening local
anesthetic toxicity.
The foundation for sparking interest among anesthesia professionals for lipid emulsion
infusion for treatment of LAST is based on published studies involving animal models. In 1998,
Weinberg and colleagues reported the first laboratory observation suggestive of supporting lipid
infusion in both prevention and treatment of bupivacaine overdose. The case involved a
pretreatment protocol and resuscitation protocol experiment in rat models. In the pretreatment
group, the rats received pretreatments of saline or lipid emulsion and then received a 0.75%
bupivacaine hydrochloride dose to induce asystole for a period of 10 seconds. In the resuscitation
protocol experiment, rat models were administered a range of bupivacaine bolus doses followed
by either a saline or lipid emulsion dose, and then a continuous infusion. The results of this study
showed bupivacaine doses to produce asystole in rats are increased when pretreated with lipids.
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As in pretreatment, lipid emulsion improved mortality from large boluses of bupivacaine at doses
producing asystole compared to saline treated control rats (Weinberg et al., 1998). The
resuscitation data relayed in this publication support limited explanation especially when
attempting to link the findings with relevance to clinical practice. The phenomenon surrounding
the mechanism of action in lipid emulsion treatment, as well as optimal dosing or concentration
of the lipid infusion was not determined by this research. This study only evaluated immediate,
short term cardiovascular outcomes and did not consider long term survival rates, neurological
function, or cardiac performance (Weinberg et al., 1998).
Weinberg and investigators continued to search explanations for the mechanisms in
which lipid emulsion treats severe bupivacaine cardiac toxicity. In 2006, a study was conducted
in isolated rat hearts to better validate the hypothesis that lipid resuscitation reduces cardiac
bupivacaine content in bupivacaine induced asystole (Weinberg et al., 2006). The experiment
compared controls without lipid infusion and hearts getting lipid immediately after an infusion of
bupivacaine. Both cardiac tissue and bupivacaine efflux from hearts with and without lipid
infusion were compared. First heart beat and hemodynamic recovery was evaluated with
subsequent findings of a more rapid return of spontaneous circulation and full recovery of
cardiac function in hearts receiving lipid emulsion doses. Although this animal study does not
rule out alternate mechanisms to which lipid emulsion infusion works, the findings are consistent
with today’s most accepted hypothesis of “lipid sink.”
Another animal study evaluated the effectiveness of lipid emulsion infusion using saline
as a control group and experimental lipid infusion following local anesthetic induced toxicity in
dogs by injection of large doses of bupivacaine. Lethal doses of bupivacaine were administered
to dogs and resuscitation was initiated by internal cardiac massage followed by either a saline or
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lipid infusion. Both the control and experimental groups developed hemodynamic changes;
however, dogs treated with saline led to progressing asystole and eventually death. Rapid
hemodynamic recovery was observed among all the lipid treated dogs. Further trials included in
the study introduced a 10 minute lag time between the symptomatic presentation of cardiac
toxicity and subsequent lipid infusion therapy. The delay in infusion initiation is to better
simulate a typical clinical scenario where the antidote may not be readily available or where
practitioners may delay lipid treatment due to failure in rapidly recognizing LAST symptoms
(Bern, Akpa, Kuo, & Weinberg, 2011). The study using non-rodent models helped to determine
the effectiveness of lipid emulsion infusion in larger species as well as providing basis to the
value lipids exhibit in aiding to the return of normal hemodynamics in acute bupivacaine toxicity
(Weinberg, Ripper, Feinstein, & Hoffman, 2003).
An experimental case report was published in 2010 in anticipation of gaining a more
concrete understanding of the resuscitation effects surrounding administration of vasoactive
drugs in conjunction with lipid emulsion therapy in treatment of cardiac arrest and
cardiovascular collapse secondary to local anesthetic toxicity. The investigation involved rabbit
models undergoing bupivacaine induced cardiac arrest. Twenty sedated rabbits received a
lOmg/kg IV bupivacaine bolus to produce asystole. Ventilation was controlled mechanically and
a nonintervention period of 30 seconds after asystole was instituted to mimic clinical practice
and response time. Chest compressions were initiated after the lag period commenced. At 1
minute, all twenty subjects received 20% lipid emulsion and either epinephrine or saline was
administered over the subsequent 10 seconds. Four experimental groups were designed,
comprising of the following treatments: a control group receiving saline; low dose epinephrine
group given 2.5 pg/kg; intermediate-dose epinephrine animals administered 10 pg/kg; and a 100
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pg/kg high dose epinephrine group. A repeat injection of lipids was administered to all groups at
the 4 minute interval. Chest compressions, mechanical ventilation, and hemodynamic monitoring
was continued for 15 minutes or until spontaneous circulation returned. The animals in the
control, lipid only group were given high dose epinephrine treatment after the 15 minute
resuscitation phase and were monitored for 20 minutes. Results showed epinephrine’s capability
of attaining return of spontaneous circulation at immediate and high doses. The correlation of
return of spontaneous circulation and epinephrine administration was further evident in
circulatory recovery after late high dose epinephrine administration in the models initially treated
with lipids alone. However, animals treated with epinephrine subsequently demonstrated
hemodynamic measurements threatening survival. Whereas, lipid emulsion alone resulted in a
less rapid return of circulatory function but sustained viability. The association between the
epinephrine response and compromised outcomes in the experimental animals receiving
vasoactive medication provides laboratory data supporting retention of epinephrine use. With the
conclusion of this research, the authors suggest conducting further studies to better define the
role of epinephrine in lipid emulsion therapy (Harvey, Cave, Prince, & Lahner, 2010).
The AANA Journal recently published a study that evaluated the effectiveness of
combined lipid emulsion and advanced cardiac life support (ACLS) following LAST and
hypoxia induced cardiovascular collapse in unanesthetized swine. Twenty four swine were
observed following administration of lethal doses of bupivacaine in conjunction with mechanical
airway obstruction with a period of hypoxia. Following complete cardiovascular collapse, ACLS
was initiated and the animals were randomized to receive either 20% lipid emulsion or saline.
The lipid emulsion or saline was administered as a bolus injection of 4 mL/kg over 2 minutes,
followed by a continuous infusion with concurrent ACLS resuscitation. Resuscitation efforts
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continued until return of spontaneous circulation or for 25 minutes. Hemodynamic variables
suggestive of viability were compared, as well as the period of time required to achieve return of
spontaneous circulation. The results of this study failed to demonstrate the effectiveness of lipid
emulsion therapy in a combined bupivacaine and hypoxia induced cardiovascular collapse in an
awake, unanesthetized swine model (Bushey, Auld, Volk, & Vacchiano, 2011).
This unique study combined 2 distinctive criteria from previous animal data: bupivacaine
toxicity in an unanesthetized animal subject further exacerbated with a period of hypoxia. This
design was significant in gaining perspective of a clinical scenario involving an awake patient
receiving a major plexus block who experiences respiratory and cardiac compromise secondary
to inadvertent intravascular injection of local anesthetic (Bushey, Auld, Volk, & Vacchiano,
2011). Research data relays conflicting animal studies regarding the efficacy of lipid emulsion
therapy. Laboratory research continues to be conducted to better define the treatment guidelines
for lipid emulsion therapy.
Approximately eight years after the first animal model of lipid rescue was documented,
the first case report detailing a successful rescue using lipid emulsion in a patient with LAST was
published. This clinical translation was very suggestive of the reported observations in animal
experiments, thereby gaining significant ground in the acceptance of lipids as an antidote for
local anesthetic toxicity. Rosenblatt and colleagues published the first case report detailing the
successful resuscitation of local anesthetic toxicity using intravenous lipid emulsion therapy
(Rosenblatt et al., 2006). This human case report involved a 58 year-old male who developed
neurological and cardiovascular symptoms, ultimately leading to prolonged cardiac arrest
immediately following the placement of an interscalene block with bupivacaine and
mepivacaine. After appropriately identifying the brachial plexus using the nerve stimulator
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technique, injection of 40 raL local anesthetic solution (20 mL, 0.5% bupivacaine and 20 mL,
1.5% mepivacaine) in 5 mL increments took place without aspiration of blood, report of pain, or
parasthesia. The patient was awake and alert throughout the procedure; however, approximately
30 seconds after removing the stimulator needle the patient became incoherent and developed a
tonic-clonic seizure. Immediate resuscitation using ACLS failed. Additionally, propofol was
administered throughout initial resuscitation efforts without clinical response. Approximately 20
minutes after the onset of cardiovascular collapse, a 20% lipid emulsion bolus was administered
and preparation for cardiopulmonary bypass was underway. Within 15 seconds, the cardiac
rhythm was restored to normal sinus rhythm and hemodynamic stability was achieved. A lipid
infusion was started and continued for 2 hours in duration. The patient recovered without
neurological deficits or adverse effects from lipid infusion therapy. The favorable outcome in
this event built the cornerstone for lipid emulsion as a potential therapeutic modality.
Dr. Rosenblatt and colleagues reported case demonstrated the clinical efficacy of lipid
rescue, while leaving some questions unanswered. Dr. Weinberg wrote an editorial review
commenting on the application of lipid emulsion therapy in the above case scenario. Although it
was recognized that research still be conducted to determine the optimal dose, rate, duration of
infusion, and upper safety dosing limit, he emphasized the importance of Rosenblatt and her
team in providing evidence in support of lipid emulsion use. He further commentated on the
importance of having 20% lipid emulsion readily available for use in all operating rooms,
regional anesthesia block rooms, obstetric units, and other surgical suites where local anesthetics
are administered (Weinberg, 2006).
This initial case report sparked publication of cases detailing rapid recovery of patients
presenting with LAST. A report of an elderly female who inadvertently received 40 mL 1%
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ropivacaine for a brachial plexus block soon appeared after the first published case. Fifteen
minutes after injection, the patient complained of dizziness and drowsiness which progressed
into a generalized tonic-clonic seizure, followed by cardiac arrest. After 10 minutes of
unsuccessful cardiopulmonary resuscitation efforts, a 20 % lipid emulsion infusion was injected
as a bolus followed by a continuous drip. Electrical activity was restored after a total dose of 200
mL. The patient was transferred to the intensive care unit and extubated shortly after. The patient
was discharged home after 4 days without negative sequelae. Upon further review of this
scenario, it was reported that the incident occurred due to a misunderstanding between the
anesthesiologist and the nurse anesthetist as 1 % ropivacaine was injected instead of 40 mL of
0.5 % ropivacaine. The cardiovascular collapse described was attributed to ropivacaine
absorption following accidental overdose. The case not only reiterated the importance of
effective communication, it also provided evidence to consider lipid infusion in cases of local
anesthetic toxicity when conventional resuscitation has been unsuccessful (Litz, Popp, Stehr, &
Kock, 2006).
An interesting case report, published in 2007, described a 75 year old female who
received levobupivacaine for surgical repair of a fractured femur neck. Foxall, McCahon, Lamb,
Hardman, & Bedford (2007), described a case in which a lumbar plexus block was placed after
several unsuccessful attempts at placing a subarachnoid block. The lumbar plexus block was
performed using 20 mL total of levobupivacaine 0.5% injected slowly into the psoas muscle after
several negative aspirations. Seconds following administration of the local anesthetic, the patient
was unresponsive, experienced a tonic-clonic seizures, and widening QRS complex with a
palpable carotid pulse. The patient’s airway was managed and secured with endotracheal tube
intubation. Within 4 minutes of the levobupivacaine injection, she received 100 mL of 20% lipid
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emulsion bolus over 5 minutes. During the lipid infusion bolus, her electrocardiogram
morphology normalized with return of a stable arterial blood pressure and heart rate. 10 minutes
following administration of the lipid emulsion bolus, the patient proceeded with the surgical
procedure. The patient had an uneventful postoperative recovery phase and regained
consciousness after the two hour surgical procedure.
Foxall et al. (2007) reported the first case report of the successful use of lipid emulsion in
situation where a patient received the bolus to reverse local anesthetic toxicity that had not
progressed to cardiac arrest. Prior human case reports demonstrated the importance in initiating a
lipid emulsion infusion only after unsuccessful resuscitation measures. Although it is impossible
to predict whether the patient’s outcome would be unchanged if intravenous lipid emulsion
therapy hadn’t been initiated until cardiovascular collapse occurred, this case report provides
beneficial evidence to clinicians to use lipids in a near cardiac-arrest situation.
In 2008, Anesthesia & Analgesia published the first case report of lipid rescue therapy in
a child. Ludot, Tharin, Belouadah, Mazoit, & Malinovsky (2008) relayed events of a 13 year old
child scheduled for knee surgery with placement of a posterior lumbar plexus block under
general anesthesia. After an uncomplicated anesthetic induction, the posterior lumbar plexus
block was achieved using a 20 mL total volume of mixture containing equal amounts of 1%
lidocaine with added epinephrine 1:200,000 and 0.75% ropivacaine. Vital signs remained
unchanged throughout administration and the solution was administered in divided doses of 3
mL after negative aspiration. A ventricular arrhythmia occurred 15 minutes after the end
injection of the local anesthetic mixture. Her blood pressure remained stable, end-tidal carbon
dioxide unchanged, and her arterial oxygen saturation decreased to 92%. The anesthesia
practitioner quickly suspected local anesthetic toxicity and 20% lipid emulsion was rapidly
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injected over 3 minutes. Within 2 minutes her electrocardiogram returned to normal complex
QRS with noted ST depression, which persisted for approximately 30 minutes. The clinicians
elected not to initiate an infusion due to her hemodynamic stability.
Not only did this case provide clinical evidence of the effectiveness of lipid emulsion
infusion for LAST in the pediatric patient population, it also gained precedence for the theory
suggesting one formulation of lipid emulsion superior over another. In this particular scenario, a
pediatric 20% lipid emulsion routinely used for intravenous nutrition of pediatric patients was
used. The lipid formulation described in previous human case reports differed from this unique
case, therefore suggesting effectiveness among a variety of preparations.
The only obstetric case published to date of a parturient receiving lipid reversal for
bupivacaine toxicity was reported in 2007 by Andrew G. Spence. An 18 year old primagravida,
presenting at 38 weeks gestation, received lipid emulsion therapy for signs and symptoms
suggestive of LAST. Epidural anesthesia was requested and was performed in the sitting
position, at the L1-L2 interspace utilizing the loss of resistance to saline technique. The patient
received a 4 mL lidocaine 2% test dose with negative response for intravenous or spinal effects
after 5 minutes. An initial bolus injection of bupivacaine 0.25% was given with good pain relief
within 10 minutes. The epidural catheter was later injected with 100 pg fentanyl and 10 mL of
bupivacaine 0.5% in anticipation of cesarean delivery. The patient responded with agitation,
restlessness, and eventually became unresponsive with noted twitching of her face and
extremities. The practitioner again aspirated the epidural catheter, revealing obvious venous
blood and confirming inadvertent intravascular injection of bupivacaine. Two lipid emulsion
therapy boluses of 50 mL 20% lipid, were initiated in a timely response, with return of
consciousness within 30 seconds. The remaining 400 mL of lipid infusion was administered and

LIPID EMULSION THERAPY

18

an emergency cesarean delivery was performed under general anesthesia. The neonate and
mother were discharged home without further complications. This report provides both clinical
evidence and reaffirmation in the proposed clinical efficacy of lipid emulsion therapy, as local
anesthetic toxicity in pregnancy remains a critical issue (Spence, 2007).
It has been proposed that with the emerging technologies of ultrasound guided regional
anesthesia a decrease in the overall incidence of local anesthetic toxicity will occur. The use of
ultrasound has the potential to provide a more precise local anesthetic deposition at the neural
target, ultimately leading to a decreased required dose of drug. However, evidence is
inconclusive in determining a reduction in local anesthetic toxicity when ultrasound guidance for
regional anesthesia is employed (Dillane & Tsui, 2010). In fact, recent research has been
conducted and relayed that ultrasound guidance may reduce, but not eliminate the most common
complications associated with regional anesthesia: blood vessel puncture, inadvertent
intravascular injection, or intraneural injection of local anesthetic (Hadzic, Salla-Blanch, & Xu,
2008).
Case studies have been published specifically surrounding adverse events of vascular
puncture occurring under ultrasound guided regional anesthesia blockade. A 82 year old women
scheduled for an excision of toe osteophytosis experienced cardiac arrest during a combined
ultrasound guided and nerve stimulation sciatic nerve block. The clinician performing the block
documented ultrasound guidance visualization of the main landmarks as well as observing an
appropriate neurostimulation response. Following multiple negative aspiration tests, 20 mL 0.5%
ropivacaine and 50 pg clonidine were injected over approximately 90 seconds. Within seconds
of injection, the patient became unconscious and experienced a tonic clonic seizure. Her airway
was immediately secured and the seizure was stopped with the administration of thiopental and
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suxamethonium. One minute following the seizure activity, ventricular fibrillation occurred and
chest compressions were initiated. Two defibrillations were required to return to the patient’s
initial rhythm of atrial fibrillation and obtain hemodynamic stability. Amiodorone and a 20%
lipid emulsion infusion were administered upon transfer to the intensive care unit. The patient
had an uneventful recovery and was discharged without negative neurologic sequelae (Gnaho,
Eyrieux, & Gentili, 2009).
Gnaho and colleagues (2009) postulated accidental intravascular injection associated with
nerve stimulation and patient motor movement. Additionally, they suggested the possibility of
the ultrasound probe compressing the vascular structures causing an obstructed view of an
intravascular placement of the insulated needle. Although a clear understanding of what the exact
fault in technique may have been was not established from this case study, it provides further
evidence of the beneficial effects of lipid emulsion therapy as treatment for LAST.
Amongst case reports of successful use of lipid emulsion therapy in resuscitation for local
anesthetic systemic toxicity, ineffectiveness of lipid infusion administration has been published.
A 51 year old female, 57 kg, planned for left hallux valgus surgery under an ultrasound guided
sciatic nerve block suffered from neurological symptoms after injection of 30 mL of a 50/50
mixture of lidocaine 20 mg mL and ropivacaine 7.5 mg mL solution. Five minutes later, a
saphenous nerve block was achieved by administering 100 mg of lidocaine. Aveline, Cognet and
Bonnet (2010) report the patient experienced agitation, confusion, and jerking movements thirty
minutes after the sciatic nerve block injection (Aveline, Gognet, & Bonnet, 2010).
Cardiovascular collapse did not occur; however, two minutes following timely administration of
100 mL lipid emulsion bolus, the patient remained unresponsive with persisting jerky
movements. A second bolus was administered without apparent change in patient status. Elective
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tracheal intubation was performed with thiopental and suxamethonium and immediate
improvement of neurological symptoms resulted. The patient underwent extensive metabolic and
electrolyte evaluations, as well as a thorough neurological examination; findings were concluded
to be normal.
Unique considerations arise with the documentation of this case report. It describes an
incidence of unsuccessful reversal of LAST with lipid therapy, as well as addresses the use of
ultrasound guidance with resulting toxicity. Discussion provided by the clinicians hypothesized
the ineffective use of lipid emulsion therapy in reversal of lidocaine induced toxicity as lidocaine
is less lipid soluble than ropivicaine or bupivacaine. The patient’s current medical regimen was
also discussed as she was taking carbamazepine for treatment of trigeminal neuralgia. They
concluded with recommendations of instituting lipid emulsion therapy only in an event where
lipid-soluble local anesthetic intoxication occurs.
An editorial in response to Aveline et al. (2010) was published in the European Journal
o f Anaesthesiology in 2011. Undoubtedly both authors agreed that the patient exhibited
symptomology suggestive of LAST, however speculations of the ineffective result of lipid
emulsion therapy differed. Uncles, Willers, Samuels, & Chaklader (2011) acknowledged the
timely recognition and accurate diagnosis of LAST, but suggested possible explanations for the
failure of lipid treatment in the case report. Calculation of the cumulative administered dose of
lidocaine injected with the combination sciatic and saphenous nerve block overcomes the
recommended maximum dose of plain lidocaine with a total of 7.02 mg/kg. Central nervous
system signs of LAST may be explained by both the systemic absorption of the increased dosing
regimen, as well as the additive effect of the ropivacaine component in the mixture (Uncles,
Willers, Samuels, & Chaklader, 2011). The editorial further discussed the possibility of drug
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interference and protein binding in relation to the combined administration of carbamazepine,
lidocaine, and ropivacaine. Due to the risk of competition for protein binding sites leaving a
higher amount of free, unbound local anesthetic, a larger volume of lipid emulsion
administration may have been necessary.
Discussion
Local anesthetic toxicity and lipid rescue resuscitation remains on the forefront of
discussion surrounding anesthesia clinical practice. Intravascular injection of local anesthetics
remains a major risk of regional anesthesia and peripheral nerve blocks even considering the
emerging technological advances of ultrasound guidance. Animal studies, ongoing clinical
research, and case reports have demonstrated the effectiveness of lipid infusion in treating
cardiovascular collapse due to LAST. With the increasing use of local anesthetics in
perioperative regional anesthesia and labor suites, anesthesia providers who deliver potentially
dangerous doses of local anesthetics must be able to rapidly recognize and effectively manage
LAST in order to facilitate recovery.
Interpretation
Although promising animal research conducted in the 1990s and the first human case
reports of lipid rescue emerged in the mid-2000s, the appropriate management and technique of
resuscitation remains an evolving topic. Discussion continues surrounding the mechanism of
action in lipid resuscitation as well as variations in methods for treating LAST. However, the
evidence of benefits and lack of apparent risk continues to guide an overall acceptance of lipid
emulsion therapy administration in the setting of LAST.
Following a thorough critique of published case reports, there is evidence of clear
discrepancies between the recommended guidelines and management set forth by ASRA and
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what is actually being translated into clinical practice. Controversies surrounding the underlying
mechanisms of action of lipid emulsion, the risks associated with administeri ng intravenous lipid
emulsion therapy, delay of administration, and the optimal lipid emulsion dose remains. Because
there is no ethical way to conduct clinical trials involving local anesthetic toxicity, further case
reports and animal studies are warranted. With continued lab investigation and further study of
the outcomes of patients who received lipid emulsion therapy for LAST, clarification of the ideal
timing of lipid emulsion therapy, along with identification of adverse events and long term
effects may certainly be achieved.
Outcome/Dissemination
Following a comprehensive review of literature, the information was gathered and
organized into a both a formal presentation and clinical reference brochure. The clinical literature
data and treatment guidelines were provided to CRNAs and ancillary operating room staff at
three local anesthetic toxicity workshop sessions at Sanford Health, Fargo, North Dakota, and
will be delivered to attendees of the North Dakota Association of Nurse Anesthetists bi-annual
meeting in Bismarck, North Dakota. Effectiveness of the workshop was evaluated by a
participant course examination at the end of the session. An evaluation tool was distributed at the
North Dakota Association of Nurse Anesthetists fall meeting to assess the quality of the
PowerPoint presentation.
Implications for Nursing
In 2010, the ASRA and Pain Medicine Practice Advisory on LAST made a streamline
effort in providing evidence-based recommendations and guidelines regarding the prevention,
diagnosis, and treatment of local anesthetic toxicity. A constant amongst the majority of recent
clinical case reports is the guidelines set by ASRA. Recommendations for treatment of LAST
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begin with timely recognition of symptoms followed by prompt, effective airway management.
Benzodiazepine administration is appropriate if seizure activity is to occur. However, if
benzodiazepines are not readily available, a small dose of propofol may be administered. If
cardiac arrest occurs, standard ACLS treatment should be followed with appropriate
modifications including: smaller (10-100 pg) epinephrine boluses for the adult, avoid the use of
vasopressin, calcium channel blockers and (3-adrenergic blockers, and finally, initiate
amiodorone for the treatment of ventricular arrhythmias. The use of lidocaine or procainamide is
not recommended. Lipid emulsion dosing guidelines, as outlined by ASRA, recommend
administering a 1.5 mL/kg 20% lipid emulsion bolus at the first signs of LAST, after airway
management. A subsequent infusion of 0.25 mL/kg per minute should be continued for 10
minutes after cardiovascular stability has been achieved. If refractory circulatory arrest occurs, a
repeated bolus and increased infusion rate to 0.5 mL/kg per minute may be considered. The
upper limit for initial dosing is defined as 10 mL/kg lipid emulsion for 30 minutes (Neal et al.,
2010). Cardiopulmonary bypass remains an appropriate treatment modality in the occurrence of
an unsuccessful resuscitation attempt with lipid emulsion and vasopressor therapy.
With the addition of guidelines for optimizing the treatment of LAST and the growing
number of clinical case reports documenting lipid infusion for patients with local anesthetic
toxicity, a couple of clinical pearls have been identified. Recent case reports support initiation of
lipid emulsion therapy at onset of local anesthetic toxicity symptoms rather than delaying
administration until standard resuscitation measures fail (Weinberg, 2008). Additionally, the
advisory council does not favor one formulation of lipid emulsion solution over another.
However, it is important to refrain from using propofol as a substitute for lipid emulsion therapy
due to its low lipid content and high cardiac depressant effects (Neal et al., 2010).
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Based upon the successful data reported from both animal studies and case reports, lipid
emulsion therapy remains an effective treatment of toxic overdose from local anesthetics and
reversal of associated cardiovascular symptoms. Lipid emulsion therapy can be instrumental in
the resuscitation of a toxic event and should be employed at the onset of neurological or
cardiovascular symptoms. In the event of local anesthetic toxicity, early recognition and timely
administration requires the availability of lipid emulsion therapy in arenas where local
anesthetics are commonly used. Operating rooms, obstetric suites, and areas where regional
blocks are conducted should keep an IV lipid emulsion supply and dosing protocol readily
available. Proficient and effective resuscitation efforts require prompt intervention and vigilance
by anesthesia clinicians in instituting both timely ACLS and lipid emulsion therapy.
Summary
Although rare, local anesthetic toxicity remains a potentially fatal complication of
regional anesthesia that cannot be solely prevented by any single measure (Bern et al., 2011).
Symptoms of LAST initially manifest primarily through neurological excitation and
cardiovascular dysfunction, and eventually progress to refractory cardiovascular arrest.
Treatment of local anesthetic toxicity is aimed at providing adequate oxygenation, instituting
ACLS, and prompt administration of lipid emulsion therapy. Guidelines for the use of lipid
emulsion therapy in treatment of severe local anesthetic toxicity have paved the way for a
promising treatment modality and reliable reversal of local anesthetic toxicity.
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